

# Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.

NCT07423013

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Peking University Third Hospital
Enrollment	50 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Able to comply with the study procedures and voluntarily sign the written informed consent form;
- Male or female subjects aged 18-80 years (inclusive) at screening;
- Body weight between 45 and 100 kg (inclusive);
- Meet internationally recognized diagnostic criteria for TED who are receiving teprotumumab N01 treatment
- Diagnosed with TED at both the screening and baseline visits;

... and 1 more (see full listing online)

### Exclusion (27)

- Poorly controlled thyroid function, defined as FT3 or FT4 deviating by more than 50% from the normal reference range;
- Receipt of radioactive iodine therapy within 3 months prior to screening;
- Thyroid dysfunction-related optic neuropathy, defined as any of the following occurring within the past 6 months due to optic nerve involvement: a decrease in best-corrected visual acuity (BCVA) of e2 lines, new visual field defects, or secondary color vision impairment;
- Corneal ulcer without improvement after treatment, as judged by the investigator;
- A decrease in CAS score of e2 points at baseline compared with screening;

... and 22 more (see full listing online)

## Locations (1 total)

---

Peking University Third Hospital, Beijing, China